###### Significance of this study

What is already known on this subject?
======================================

-   Intraductal papillary mucinous neoplasms (IPMN) and pancreatic intraepithelial neoplasia (PanIN) are precursors to pancreatic ductal adenocarcinoma (PDAC).

-   Understanding the molecular mechanisms that drive precursor formation and progression can improve PDAC outcomes.

-   *ARID1A* is frequently mutated in PDAC.

-   *Arid1a* loss in mice leads to IPMN formation that may be mediated by *Sox9* and the mTor (mammalian target of rapamycin) pathway.

What are the new findings?
==========================

-   Duct-specific *Arid1a* loss induces duct enlargement and tumourigenesis.

-   Acinar-specific *Arid1a* heterozygous deletion results in accelerated PanIN formation and worse outcomes.

-   *ARID1A* loss in cultured pancreatic duct cells leads to MYC overexpression and increased protein synthesis.

-   *ARID1A* deletion in cultured pancreatic duct cells leads to broadly increased enhancer/promoter histone marks.

How might it impact on clinical practice in the foreseeable future?
===================================================================

-   Insights into the mechanisms that drive premalignant PDAC lesions may lead to novel therapeutic strategies against this lethal disease.

Background {#s1}
==========

Pancreatic ductal adenocarcinomas (PDAC) can arise out of multiple types of precursor lesions such as pancreatic intraepithelial neoplasia (PanIN) or intraductal papillary mucinous neoplasms (IPMNs).[@R1] Large-scale sequencing studies have defined the genomic profile of PDAC being dominated by mutations in *KRAS*, *TP53*, *SMAD4* and *CDKN2A* followed by a 'long tail' of the remaining mutations that occur in 10% or less of samples.[@R2] The most common of these mutations include *ARID1A*, which is also altered in 10% of IPMN.[@R4]

ARID1A is part of the SWI/SNF complex, which is a multisubunit complex that remodels chromatin by shifting, inserting or evicting nucleosomes in an ATP-dependent manner.[@R6] Combinatorial assembly of subunits provides the SWI/SNF complex tissue and temporal specificity in gene regulatory functions that may be activating or repressive.[@R8] ARID1A is thought to modulate the chromatin remodelling activity of the SWI/SNF complex through direct interactions with DNA and by recruiting and binding transcriptional cofactors.[@R9] While it is presumed that *ARID1A* is a tumour suppressor gene because of widespread loss-of-function mutations found in human cancer samples,^10^ the effects of *ARID1A* loss in the pancreas and PDAC have generally not been well-characterised, with the exception of a recent study showing that pancreatic *Arid1a* loss led to IPMN formation which may be mediated through *Sox9* expression and the mTor  (mammalian target of rapamycin) pathway.[@R11]

Protein synthesis is increased by almost all oncogenic signalling pathways including RAS, WNT--β‐catenin and PI3K--mTOR.[@R12] Aberrantly increased translation supports the transformation of normal cells and the acquisition of various hallmark features, such as angiogenesis, altered metabolism and proliferation. The MYC pathway also increases translation. Previous studies have shown that protein synthesis driven by MYC can be oncogenic, and mitigation of the aberrant translation suppresses MYC's oncogenic activities.[@R13]

In this study, we characterised the effects of pancreas-specific *Arid1a* loss in mice. We found that pan-pancreatic *Arid1a* deletion synergised with an activating *Kras* mutation to induce IPMN. Using lineage-specific Cre expression systems, we found that *Arid1a* loss in pancreatic duct cells resulted in cystic dilation of ducts and PDAC, while heterozygous *Arid1a* deletion in the acinar compartment accelerated PanIN and PDAC formation. *Arid1a* loss in murine pancreata induced gene signatures associated with *Myc* activity and protein translation. Using human pancreatic ductal epithelial (HPDE) cells, we confirmed that *ARID1A* loss led to elevated protein expression mediated by MYC overexpression and a global increase in H3K27ac marks. Finally, we tested EZH2 inhibition as a way to blunt *Arid1a* loss-induced IPMN.

Materials and methods {#s2}
=====================

Please see online [supplementary materials and methods](#SP4){ref-type="supplementary-material"}.
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Results {#s3}
=======

*Arid1a* loss is sufficient to initiate inflammation, PanIN and mucinous cysts {#s3a}
------------------------------------------------------------------------------

To determine the functional effects of *Arid1a* loss in pancreas, we generated *Ptf1a-Cre*; *Arid1a^f/f^* (referred henceforth as CA) mice. Exon 8 of *Arid1a* is flanked by loxP sites and tissue specificity was achieved with Cre under regulatory control by *Ptf1a*, which is a transcription factor that is expressed in all pancreas cell types starting around E9.5 (online [supplementary figure S1A](#SP1 SP2){ref-type="supplementary-material"}).[@R14] These mice were viable, fertile and appeared grossly normal. *Arid1a* was deleted without alternatively spliced gene products or truncated proteins when bulk pancreata was examined with western blotting (online [supplementary figure S1B](#SP1 SP2){ref-type="supplementary-material"}).[@R16] However, on closer examination of individual cellular compartments, we found that *Arid1a* deletion was complete in acinar cells, partial in ductal cells and almost none in the endocrine cells ([figure 1A](#F1){ref-type="fig"}). When we used the *Rosa-LSL-tdTomato* reporter to track Cre expression, we found that tomato was expressed in essentially all cells, consistent with previous reports (online [supplementary figure S1C](#SP1 SP2){ref-type="supplementary-material"}).[@R15] This pattern of *Arid1a* deletion by *Ptf1a-Cre* is consistent with results shown by other groups.[@R11]

![Conditional deletion of *Arid1a* in the pancreas induces inflammation, pancreatic intraepithelial neoplasia (PanIN) and mucinous cysts. (A) In wild-type mice, ARID1A was expressed in most acinar cells (red arrowheads), all duct cells ('D' adjacent) and all islet cells (asterisk). In *Ptf1a-Cre*; *Arid1a* ^*f/f*^ (CA) mice, ARID1A was lost in all acinar cells (yellow arrowheads), some duct cells (red arrows point to lost, red arrowheads point to retained) and none of the islet cells. ­­ Sixteen-week-old CA mice formed (B) PanIN and (C) large cysts with flat to cuboidal epithelium with papillary projections (arrows) that were Alcian blue and claudin-18 positive. Both PanIN and cysts showed focal ARID1A positivity (arrowheads point to ARID1A-positive cells). (D) The cysts expressed embryonic factors PDX1 and HNF4a. (E) The pancreata of CA mice showed significant upregulation of chemokines and cytokines, as measured by quantitative PCR, n≥5, \*P\<0.05, \*\*P\<0.01.  ](gutjnl-2017-315490f01){#F1}

By 4 months of age, many CA mice developed acinar to ductal metaplasia (ADM, 12 of 14 mice, online [supplementary figure S1D](#SP1 SP2){ref-type="supplementary-material"}), which is a process where acinar cells respond to injury or stress by downregulating digestive enzymes, expressing duct-specific markers and taking on ductal phenotypes.[@R18] ADM is reversible in wild-type mice on removal of the stress; however, ADM can progress to PanIN in the setting of oncogenic *Kras*.[@R19] A significant proportion of CA mice also developed ductal lesions that were mucinous, as supported by Alcian blue staining, and appeared to be PanIN, based on morphology and claudin-18 positivity (11 of 14 mice, [figure 1B](#F1){ref-type="fig"}). Four of 14 mice formed larger cysts with some lined by bland appearing epithelium, while others had papillary projections and mucinous components that were claudin-18 positive ([figure 1C](#F1){ref-type="fig"}). ARID1A expression in PanIN and cysts were mosaic within the same lesion ([figure 1B, C](#F1){ref-type="fig"}).

Further characterisation of the cysts showed reactivation of embryonic factors PDX1 and HNF4A, which are associated with reprogramming of heretofore terminally differentiated cells into a dedifferentiated state capable of progressing down a neoplastic pathway ([figure 1D](#F1){ref-type="fig"}).[@R21] Inflammation has also been previously shown to be a key component of pancreatic reprogramming.[@R21] In CA mice, there were occasional robust inflammatory responses as demonstrated by infiltration of CD45-positive lymphoid cells and marked fibrosis (online [supplementary figure S1E](#SP1 SP2){ref-type="supplementary-material"}). This is consistent with quantitative PCR data on bulk pancreata, where multiple chemokines and cytokines, such as *Il1b*, *Il7*, *Tnfa* and *Ccl2* were elevated ([figure 1E](#F1){ref-type="fig"}). By 1 year of age, we did not observe any evidence of PDAC or significant progression of PanIN lesions. In addition, the cysts remained benign appearing, although reaching very large size in some instances, and there was also widespread adipocyte infiltration (online [supplementary figure S1F](#SP1 SP2){ref-type="supplementary-material"}). Thus, *Arid1a* loss in the pancreas was sufficient to initiate PanIN and simple mucinous cysts, but did not support further progression to higher grade dysplasia or frank carcinoma within 1 year.

*Arid1a* loss synergises with oncogenic *Kras* to accelerate IPMN formation {#s3b}
---------------------------------------------------------------------------

Activating *KRAS* mutations are found in more than 90% of human PanIN and PDAC samples and are thought to be the initiating driver event for PDAC.[@R2] As a result, a large portion of *ARID1A* mutations in human PDAC are accompanied by *KRAS* mutations. IPMN have also been found to harbour *KRAS* mutations.[@R1] To determine the effects of concomitant *ARID1A* deletion and *KRAS* activation, we generated *Kras^G12D^; Ptf1a-Cre; Arid1a^f/f^* mice (henceforth called 'KCA' mice, online [supplementary figure S2A](#SP1 SP2){ref-type="supplementary-material"}). By 8 weeks of age, *Kras^G12D^; Ptf1a-Cre* (KC) mice had significant inflammation and developed numerous PanIN that were Alcian blue positive, as expected ([figure 2A,B](#F2){ref-type="fig"}).[@R25] While KCA mice also developed inflammation and PanIN (online [supplementary figure S2B](#SP1 SP2){ref-type="supplementary-material"}), oncogenic *Kras* significantly accelerated the cyst phenotype seen in CA mice. Whereas only about 30% of CA mice developed macroscopic cysts that were occasionally mucinous or complex, all KCA mice had large mucinous cysts with papillary projections ([figure 2A,B](#F2){ref-type="fig"}). As was the case in CA mice, the KCA cysts were mosaic for ARID1A expression ([figure 2B](#F2){ref-type="fig"}).

![*Kras* activation synergises with *Arid1a* loss in the pancreas to induce intraductal papillary mucinous neoplasms (IPMNs). (A) *Kras^G12D^; Ptf1a-Cre* (KC) mice had oedema, while *Kras^G12D^; Ptf1a-Cre; Arid1a^f/f^* (KCA) mice formed large pancreatic cysts. (B) KC mice showed significant inflammation and numerous pancreatic intraepithelial neoplasia. KCA mice formed large mucinous cysts with papillary projections that were mosaic for ARID1A (arrowhead points to ARID1A-positive cells). (C) KCA cyst fluid was amylase rich (normal serum amylase \<10 U/L), suggesting a direct connection to the pancreatic ductal system, consistent with IPMN. n=4, error bars represent SEM. (D) KCA cysts with mucin expression patterns consistent with human gastric subtype IPMN. (E) Human gastric subtype (n=28) and pancreaticobiliary subtype (PB, n=10) IPMN showed areas with negative or low ARID1A staining, as compared with intestinal subtype (n=6). \*\*P\<0.01. (F) Kaplan-Meier curve estimating survival of *Kras^G12D^*; *Trp53^f/+^*; *Ptf1a-Cre* mice that were *Arid1a^+/+,^ Arid1a^f/+^* or *Arid1a^f/f^*.](gutjnl-2017-315490f02){#F2}

There are two types of mucinous pancreatic cysts, both of which can progress to PDAC. Mucinous cystic neoplasms (MCN) are cyst-forming epithelial neoplasms composed of mucinous epithelium associated with ovarian-type stroma (expressing oestrogen and progesterone receptors), which do not communicate with the pancreatic ductal system, while IPMN are intraductal, grossly visible epithelial neoplasm of mucin-producing cells, arising in the main pancreatic duct or its branches, and usually exhibiting a papillary growth pattern.[@R26] Cysts in KCA mice demonstrated papillary projections and did not stain for oestrogen and progesterone receptors (online [supplementary figure S2C](#SP1 SP2){ref-type="supplementary-material"}). Analysis of the cyst fluid showed high amylase levels, suggesting a direct connection to the ductal system ([figure 2C](#F2){ref-type="fig"}). Thus, histologic and biochemical analyses demonstrated that concurrent *Kras* activation and *Arid1a* deletion resulted in pancreatic mucinous cysts which resemble human IPMN, rather than MCN.

IPMN may be further categorised into four epithelial subtypes based on histomorphology and mucin expression patterns.[@R27] The intestinal and oncocytic subtypes progress to colloid and oncocytic adenocarcinomas, respectively, and have a more favourable outcome than PDAC not arising in these precursor lesions. Gastric and pancreaticobiliary subtypes tend to form tubular adenocarcinomas, which have significantly worse outcomes than colloid and oncocytic carcinomas, but still better than PDAC not arising in IPMN.[@R28] IPMN from KCA mice appeared to be predominantly of the gastric subtype, as most areas had short papillae and epithelium morphologically resembling gastric foveolar epithelium and did not express MUC1 or MUC2 ([figure 2B,D](#F2){ref-type="fig"}). However, there were some occasional areas that resembled the pancreaticobiliary subtype, which is characterised by more interconnected and arborising papillae composed of cuboidal cells with little mucin (online [supplementary figure S2D](#SP1 SP2){ref-type="supplementary-material"}). We did not observe any lesions resembling the intestinal subtype and further confirmed by negative CDX2 immunohistochemistry (online [supplementary figure S2E](#SP1 SP2){ref-type="supplementary-material"}).

To determine if KCA cysts represent a faithful recapitulation of human disease, we asked if ARID1A expression was lost in human IPMN. We performed a retrospective review of our institutional surgical database and identified 35 patients who underwent pancreatectomies from 2006 to 2016 and had IPMN identified on final pathology. In these patients, there were 28 gastric, 6 intestinal, 1 oncocytic and 10 pancreaticobiliary components (some patients had mixed IPMN containing more than one subtype). We performed immunohistochemistry for ARID1A and graded the expression as negative, low or high (online [supplementary figure S2F](#SP1 SP2){ref-type="supplementary-material"}). We found that 61% of gastric and 10% of pancreaticobiliary subtype IPMN had ARID1A null or low expression, whereas no intestinal type had ARID1A loss ([figure 2E](#F2){ref-type="fig"}). Even when IPMN contained cells with no or low ARID1A staining, there were pockets of strong staining consistent with the mosaic expression pattern seen in KCA mice cysts (online [supplementary figure S2G](#SP1 SP2){ref-type="supplementary-material"}). These data show that *ARID1A* loss is present in human IPMN and highlights the clinical relevance of the KCA model.

While *ARID1A* has been considered a tumour suppressor, we recently showed that it has both context-dependent oncogenic and tumour-suppressive effects in liver cancer.[@R29] To determine the effect of *Arid1a* loss on PDAC formation, we generated *Kras^G12D^; Trp53^f/+^; Ptf1a-Cre* (KPC) mice that were *Arid1a* wild-type, heterozygous or null. Surprisingly, we found no difference in survival between the three cohorts ([figure 2F](#F2){ref-type="fig"}). While we noted cancer in all three KPC groups, KPC *Arid1a*-null mice often had massive cysts replacing almost all of the pancreas (online [supplementary figure S2H](#SP1 SP2){ref-type="supplementary-material"}). Thus, it was unclear if the cause of death for KPC *Arid1a*-null mice was cancer or mass effect from the large cysts.

*Arid1a* loss in pancreatic duct cells promotes cystic duct dilation and PDAC {#s3c}
-----------------------------------------------------------------------------

Since it was difficult to discern cancer-specific deaths in the KPC system, we hypothesised that we could isolate the IPMN phenotype using the inducible duct-compartment specific *Sox9-CreER* line (online [supplementary figure S3A](#SP1 SP2){ref-type="supplementary-material"}).[@R30] Mice were given tamoxifen (TAM) after weaning at 3.5 to 4.5 weeks of age. We found that 3 to 4 months after induction *Kras^G12D^*; *Sox9-CreER*; *Arid1a^+/+^* mice remained histologically bland, while *Kras^G12D^*; *Sox9-CreER*; *Arid1a^f/f^* mice had mildly dilated pancreatic ducts ([figure 3A,B](#F3){ref-type="fig"}). We observed a progressive increase in the calibre of pancreatic ducts at 26 weeks and then 52 weeks after TAM ([figure 3B](#F3){ref-type="fig"}). At 52 weeks, we found that one of five *Kras^G12D^*; *Sox9-CreER*; *Arid1a^f/f^* mice had a mucinous cystic lesion that exhibited focal mild epithelial papillary tufting, resembling the earliest signs of IPMN formation ([figure 3A,C](#F3){ref-type="fig"}). *Kras^G12D^*; *Sox9-CreER*; *Arid1a^f/f^* mice also occasionally had significant localised inflammation and PanIN (online [supplementary figure S3B](#SP1 SP2){ref-type="supplementary-material"}), but there was no evidence of frank carcinoma or dysplasia by 1 year after TAM. Three of 15 *Kras^G12D^*; *Sox9-CreER*; *Arid1a^+/+^* mice had only very small foci of inflammation or ADM. There was no difference in proliferation in ductal cells (online [supplementary figure S3C](#SP1 SP2){ref-type="supplementary-material"}). To understand the phenotypic variation seen in the *Sox9-CreER* cohort, we performed lineage tracing using a *Rosa-LSL-tdTomato* (*Td*) reporter. We examined *Sox9-CreER; Td* mice 12 weeks after TAM and identified mosaic ARID1A expression that corresponded to tomato signal ([figure 3D](#F3){ref-type="fig"}). In addition, we found that *Sox9-CreER* mice had 36% to 98% of the CK-19 positive ductal cells showing tomato positivity (online [supplementary figure S3D](#SP1 SP2){ref-type="supplementary-material"}).

![Phenotype of *Arid1a* deletion in pancreatic duct cells. (A) Three to 4 months after tamoxifen (TAM) induction, both *Kras^G12D^; Sox9-CreER; Arid1a^+/^* ^+^ and *Kras^G12D^; Sox9-CreER; Arid1a^f/f^* mice formed small ductal lesions. Twelve months after TAM, *Kras^G12D^; Sox9-CreER; Arid1a^f/f^* mice occasionally formed large cystic lesions, while *Kras^G12D^; Sox9-CreER; Arid1a^+/+^* mice had only smaller lesions that most resembled pancreatic intraepithelial neoplasia. (B) *Kras^G12D^; Sox9-CreER; Arid1a^f/f^* mice showed progressively enlarging ducts over time. At 12 weeks, n=12 and 9, at 26 weeks, n=6 and 10 and at 52 weeks, n=15 and 5 for *Kras^G12D^; Sox9-CreER; Arid1a^+/+^* and *Arid1a^f/f^* mice, respectively. \*P\<0.05, \*\*P\<0.01. (C) Lesions in *Kras^G12D^; Sox9-CreER; Arid1a^f/f^* mice were Alcian blue positive and mosaic for ARID1A (arrow to ARID1A-negative cells and arrowhead to ARID1A-positive cells, 'D' denotes duct/cyst lumens). (D) Serial section showed that ARID1A loss in *Sox9-CreER; Arid1a^f/f^; ROSA26-LSL-tdTomato (Td)* corresponded to where tomato was expressed. Yellow dashed lines denote islets. (E) *Kras^G12D^; Trp53^f/+^; Sox9-CreER; Arid1a^f/f^* mice formed occasional pancreatic ductal adenocarcinoma that had sarcomatoid features (top panels) and incipient intraductal papillary mucinous neoplasm (bottom panels). Both lesions were ARID1A negative and tomato positive. ARID1A positivity were seen in stromal cells only.](gutjnl-2017-315490f03){#F3}

To determine if tumour suppressor loss could accelerate cancer formation, we generated *Kras^G12D^; Trp53^f/+^; Sox9-CreER; Td* mice that were *Arid1a* wild-type, heterozygous or null. A similar proportion of mice from all three genotypes developed soft tissue masses or ocular lesions that necessitated euthanasia, but no pancreas-related deaths were seen 1 year after TAM (online supplementary figure 3E). We found no pancreatic phenotypes in 14 *Kras^G12D^; Trp53^f/+^; Sox9-CreER; Arid1a^+/+^* mice and only small areas of inflammatory infiltrates in 2 of 16 *Kras^G12D^; Trp53^f/+^; Sox9-CreER; Arid1a^f/+^* mice. Of the 12 *Kras^G12D^; Trp53^f/+^; Sox9-CreER; Arid1a^f/f^* mice, 2 had ADM or early PanIN and another 2 had cystic lesions (online supplementary figure 3F). Two other mice had firm, large pancreatic tail masses that were red on gross examination, suggesting tomato expression ([figure 3E](#F3){ref-type="fig"}). On histologic examination, the masses were PDAC containing undifferentiated components with sarcomatoid features. In addition, they were ARID1A negative and tomato positive, confirming ductal origin ([figure 3E](#F3){ref-type="fig"}). One of the two mice with PDAC had areas of duct dilation with some epithelial tufting suggestive of incipient IPMN ([figure 3E](#F3){ref-type="fig"}), while the other had only PanIN-associated PDAC. In sum, these data show that *Arid1a* restrains tumourigenesis, either in the form of pre-IPMN lesions or PDAC, in ductal cells.

Heterozygous *Arid1a* loss accelerates PDAC formation {#s3d}
-----------------------------------------------------

To determine the effects of *Arid1a* loss in the acinar compartment, we used the *Ptf1a^CreER^* line to induce *Kras* and *Arid1a* mutations (online [supplementary figure S4A](#SP1 SP2){ref-type="supplementary-material"}).[@R31] *Ptf1a^CreER^* mice were given TAM between 3.5 and 4.5 weeks of age and we observed complete recombination in the acinar compartment without leakage into the duct cells or endocrine cells, consistent with previous reports ([figure 4A,B](#F4){ref-type="fig"} and online [supplementary figure S4B](#SP1 SP2){ref-type="supplementary-material"}).[@R31] We generated *Kras^G12D^*; *Ptf1a^CreER^* mice that were wild-type, heterozygous or null for *Arid1a* and observed inflammation, fibrosis and mucin-positive lesions consistent with PanIN in all three lines ([figure 4C](#F4){ref-type="fig"}). In the *Arid1a* null mice, the PanINs lacked *Arid1a *expression, consistent with acinar origin ([figure 4D](#F4){ref-type="fig"}). When we quantitated the amount of PanIN from each line by measuring the amount of claudin-18 positive lesions 16 weeks after TAM, we found *Arid1a* heterozygous mice had more PanIN than *Arid1a* wild-type mice ([figure 4E](#F4){ref-type="fig"}). Similarly, when we made *Kras^G12D^; Trp53^f/+^; Ptf1a^CreER^* mice with all three *Arid1a* states, we found that *Arid1a* heterozygous mice had the worst survival ([figure 4F](#F4){ref-type="fig"}). When we measured proliferation with Ki-67, we found no difference between the three groups (online [supplementary figure S4C](#SP1 SP2){ref-type="supplementary-material"}). While all three genotypes had moderately to poorly differentiated ductal adenocarcinomas, about 30% of mice in both *Arid1a* heterozygous and null groups had tumours with undifferentiated rhabdoid or sarcomatoid features ([figure 4G](#F4){ref-type="fig"}). *Arid1a* null mice had an intermediate phenotype with respect to both PanIN quantity and overall survival.

![Heterozygous *Arid1a* loss in acinar cells accelerates pancreatic intraepithelial neoplasia (PanIN) formation and shortens survival. (A) After tamoxifen, tomato expression in *Ptf1a^CreER^; ROSA26-LSL-tdTomato (Td)* mice was restricted to acinar cells. None was seen in islets (yellow dashed outline) or ducts (yellow arrowheads). (B) After tamoxifen, ARID1A expression was lost in acinar cells but retained in duct and islet cells in *Ptf1a^CreER^; Arid1a^f/f^* mice. (C) After tamoxifen, *Kras^G12D^; Ptf1a^CreER^; Arid1a^+/+^*, *Arid1a^f/+^* and *Arid1a^f/f^* mice all developed PanIN. (D) PanIN in *Kras^G12D^; Ptf1a^CreER^; Arid1a^f/f^* mice did not express ARID1A. (E) *Kras^G12D^; Ptf1a^CreER^; Arid1a^f/+^* formed more PanIN, n=9 for each group, \*P\<0.05. (F) *Kras^G12D^; Trp53^f/+^; Ptf1a^CreER^; Arid1a^f/+^* mice had worse survival than *Kras^G12D^; Trp53^f/+^; Ptf1a^CreER^; Arid1a^+/+^* mice. \*P\<0.05. (G) *Kras^G12D^; Trp53^f/+^; Ptf1a^CreER^* mice with heterozygous and homozygous *Arid1a* loss developed components of undifferentiated pancreatic ductal adenocarcinoma with rhabdoid or sarcomatoid features.](gutjnl-2017-315490f04){#F4}

*Arid1a* loss increases protein synthesis through the induction of *MYC* {#s3e}
------------------------------------------------------------------------

To understand the downstream transcriptional effects of *Arid1a* deletion in the pancreas, we performed RNA sequencing of pancreata collected from CA mice and their wild-type littermates. We used gene set enrichment analysis and found that the *Myc* target gene network was the highest ranked among the 'Hallmark' gene sets, suggesting that *Arid1a* loss in CA mice pancreas induced increased MYC activity ([figure 5A](#F5){ref-type="fig"} and online [supplementary table 1](#SP3){ref-type="supplementary-material"}).[@R33] We chose to focus on the ductal compartment to identify possible therapeutic targets for IPMN, as surgery is currently the only treatment option. We performed small-interfering RNA (siRNA) *ARID1A* knockdown in immortalised HPDE cells ([figure 5B](#F5){ref-type="fig"})[@R34] and found an increase in MYC protein expression ([figure 5C](#F5){ref-type="fig"}). When we performed immunohistochemistry for c-MYC, we found only weak and patchy signals in PanIN of KC mice but intense signals in the cysts of KCA mice ([figure 5D](#F5){ref-type="fig"}). Similarly, the cystic lesions in *Kras^G12D^*; *Sox9-CreER*; *Arid1a^f/f^* mice expressed c-MYC, while the duct cells in *Kras^G12D^*; *Sox9-CreER; Arid1a^+/+^* mice did not have any expression ([figure 5E](#F5){ref-type="fig"}). In both cohorts, there was very little to no signal in the acinar and islet compartments (online [supplementary figures S5A,B](#SP1 SP2){ref-type="supplementary-material"}).
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![*ARID1A* loss induces gene signatures associated with MYC activity. (A) Gene set enrichment analysis of RNA-seq of *Ptf1a-Cre; Arid1a^f/f^* (CA) pancreata using the 'Hallmark' gene sets demonstrated that the MYC target gene signature was the most upregulated signature in CA mice. NES, normalised enrichment score; FDR, false discovery rate. (B) Western blot confirmed that si*ARID1A* 1 and 2 were effective in knocking down ARID1A in human pancreatic ductal epithelial (HPDE) cells. (C) Western blot and quantification demonstrating that *ARID1A* knockdown induced MYC expression in HPDE cells. n=8, \*\*\*P\<0.001. (D) PanIN in *Kras^G12D^; Ptf1a-Cre; Arid1a^+/+^* mice had patchy c-MYC expression, while cysts in *Kras^G12D^; Ptf1a-Cre; Arid1a^f/f^* mice stained intensely for c-MYC. (E) In *Kras^G12D^; Sox9-CreER; Arid1a^+/+^* mice, acinar, duct ('D' in duct lumen) and islet (asterisk) cells had very little c-MYC staining, while cysts from *Kras^G12D^; Sox9-CreER; Arid1a^f/f^* mice expressed some c-MYC.](gutjnl-2017-315490f05){#F5}

To determine what pathways might be regulated by MYC, we analysed the RNA-seq data using the 'Molecular Signatures Database' and the top four highest ranked signatures were protein synthesis related ([figure 6A](#F6){ref-type="fig"} and online [supplementary table 1](#SP3){ref-type="supplementary-material"}).[@R33] Because MYC directly regulates ribosomal protein transcription as one way to mediate increased translation, we measured ribosomal protein expression in CA pancreata using real-time quantitative PCR and found significant elevation in *Arid1a* null tissues (online [supplementary figure S6A](#SP1 SP2){ref-type="supplementary-material"}). To more directly determine if this was a result of acute *Arid1a* loss, we measured ribosomal protein expression in *Ptf1a-CreER; Arid1a^f/f^* pancreata 1 week after TAM and also found increased expression (online [supplementary figure S6B](#SP1 SP2){ref-type="supplementary-material"}).

![*ARID1A* loss induces MYC-mediated increase in protein synthesis. (A) Gene set enrichment analysis of RNA-seq of *Ptf1a-Cre; Arid1a^f/f^* (CA) mice pancreata using the 'Molecular Signatures Database' demonstrated that the top four upregulated signatures in CA mice were associated with protein translation. NES, normalised enrichment score; FDR, false discovery rate. (B) Human pancreatic ductal epithelial (HPDE) cells were treated with O-propargyl-puromycin (OPP), which were incorporated into nascent peptides, labelled with fluorescence and quantified with fluorescence activated cell sorting (FACS). Representative FACS plot (left) and quantification (right) are shown. HPDE cells were treated siScramble (n=7), si*ARID1A* 1 (n=6) and si*ARID1A* 2 (n=6). Cycloheximide (CHX) is a translation inhibitor and served as a negative control for the assay in cells treated with siScramble (n=2). \*P\<0.05, \*\*P\<0.01. (C) Western blot demonstrating partial knockdown of MYC with si*MYC* in HPDE cells. (D) HPDE cells were treated with OPP and treated with siScramble (n=8), si*ARID1A* (n=3), si*MYC* 1 (n=7) and si*ARID1A* and si*MYC* 1 (n=3). Quantification of relative fluorescence is shown. \*P\<0.05, \*\*P\<0.01.](gutjnl-2017-315490f06){#F6}

We next investigated whether increased expression of ribosomal proteins resulted in more or less protein synthesis and quantitatively assessed protein synthesis in the context of *Arid1a* loss. We used a fluorescent-labelling assay based on the incorporation of O-propargyl-puromycin (OPP), which is taken up by ribosomes and incorporated into new peptides. We found that *ARID1A* knockdown in HPDE cells significantly increased OPP incorporation, signifying increased translation ([figure 6B](#F6){ref-type="fig"} and online [supplementary figure S6C](#SP1 SP2){ref-type="supplementary-material"}). Because MYC and mTOR drive essential signalling networks that integrate growth and proliferative signals to activate protein translation, we examined mTOR activity.[@R35] After *ARID1A* knockdown, there was no difference in mTOR activity, thus favouring MYC as the causative mechanism of protein synthesis activation (online [supplementary figure S6D](#SP1 SP2){ref-type="supplementary-material"}). To test if MYC was responsible for the increase in translation due to *ARID1A* loss, we used siRNA to partially knock down *MYC* in the setting of si*ARID1A* ([figure 6C](#F6){ref-type="fig"}). When we measured protein synthesis, we found that returning *MYC* to baseline levels in the setting of *ARID1A* knockdown led to a reduction of OPP levels comparable to the levels seen in si*MYC-*treated cells ([figure 6D](#F6){ref-type="fig"} and online [supplementary figure S6E](#SP1 SP2){ref-type="supplementary-material"}). This suggests that *MYC*, in part, mediates the control of protein translation by *ARID1A*.

*ARID1A* loss leads to increased activated enhancer/promoter marks {#s3f}
------------------------------------------------------------------

We next sought to understand the effects of *ARID1A* loss on chromatin activation. Using HPDE cells, we generated an *ARID1A-*null line using CRISPR/Cas9 (online [supplementary figure S7](#SP1 SP2){ref-type="supplementary-material"}). ChIP-seq was then performed against H3K27ac, which marks active enhancers and promoters. We found that *ARID1A* null cells had more peaks than cells with intact *ARID1A* ([figure 7A](#F7){ref-type="fig"}). When we examined genes associated with MYC and protein translation signatures, which were the most upregulated gene networks identified from RNA-seq of CA pancreata ([figure 5A](#F5){ref-type="fig"} and [figure 6A](#F6){ref-type="fig"}), both also had significantly more peaks in *ARID1A* null cells ([figure 7B,C](#F7){ref-type="fig"}). This shows that *ARID1A* loss led to increased activation of these target genes.

![*ARID1A* loss leads to increased H3K27ac marks. Metagene plot and heatmap of H3K27ac sites in human pancreatic ductal epithelial cells that were wild type (WT) or null (KO) for *ARID1A* for the given gene sets. TSS, transcription start site. (A) All genes. (B) 'Hallmark MYC Targets V2' signature from Gene Set Enrichment Analysis (GSEA). (C) 'Reactome Peptide Chain Elongation' signature from GSEA.](gutjnl-2017-315490f07){#F7}

EZH2 inhibition does not abrogate *Arid1a* mutant IPMN {#s3g}
------------------------------------------------------

Since IPMN growth is associated with PDAC risk, therapies that slow IPMN progression would be highly desirable. Previous studies have suggested that SWI/SNF deficient tumours, including those with *ARID1A* mutations, are sensitive to inhibition of EZH2, which is the catalytic subunit of the Polycomb repressive complex 2.[@R36] Thus, we asked whether *Arid1a* mutant IPMN were susceptible to EZH2 inhibition. We first confirmed that trimethylated histone H3 lysine 27 (H3K27me3), a marker of EZH2 activity, was highly expressed in KCA cysts ([figure 8A](#F8){ref-type="fig"}). Next, we treated Capan-1 pancreatic cancer cells with the potent and specific EZH2 inhibitor EPZ011989 and confirmed that it was highly effective in reducing H3K27me3 levels ([figure 8B](#F8){ref-type="fig"}).[@R37] We then performed abdominal MRI on 20 KCA mice at 3 to 4 weeks of age, when significant cyst burden was already present. Mice were randomised to vehicle or EPZ011989 and stratified based on gender and cyst volume. After 4 weeks of therapy, repeat MRIs were performed ([figure 8C](#F8){ref-type="fig"}). We found that mice treated with EPZ011989 gained less weight than vehicle-treated mice ([figure 8D](#F8){ref-type="fig"}) and that the compound effectively reduced H3K27me3 levels in the pancreata of the treatment group ([figure 8E](#F8){ref-type="fig"}). However, we found no difference in cyst volumes between the two groups ([figure 8F](#F8){ref-type="fig"}). We also did not find any differences in proliferation and apoptosis in the cysts (online [supplementary figure S8](#SP1 SP2){ref-type="supplementary-material"}). Thus, *Arid1a* mutant IPMN epithelial cells did not respond to EZH2 inhibition *in vivo*.

![EZH2 inhibition does not block intraductal papillary mucinous neoplasm growth in *Kras^G12D^; Ptf1a-Cre; Arid1a^f/f^* (KCA) mice. (A) Immunohistochemistry showing KCA murine cysts expressed high levels of H3K27me3. (B) Western blot showing that Capan-1 cells treated with EPZ011989 had decreased levels of H3K27me3. (C) Treatment plan, n=10 for each arm (vehicle and EPZ011989). Day 1 was defined by when the first dose was given. (D) Mice treated with EPZ011989 had a lower rate of weight gain than mice treated with vehicle. (E) Pancreata from the treatment group had decreased H3K27me3 levels on western blot. (F) Representative coronal section of MRI from vehicle and EPZ011989 treated KCA mice before and after treatment (arrowheads pointing to cysts, which were fluid filled, thus showing up as white signal on T2 weighted MRI). There was no difference in the change in volume after EPZ011989 treatment. AU, arbitrary unit. BID, two times daily.](gutjnl-2017-315490f08){#F8}

Discussion {#s4}
==========

SWI/SNF components are frequently mutated in a variety of cancers, including PDAC.[@R38] Although *ARID1A* is the most commonly mutated SWI/SNF subunit in PDAC, the functional effects of *ARID1A* alterations are unclear.[@R2] To clarify the effects of *ARID1A* mutations in pancreatic neoplasms, we generated pancreas-specific *Arid1a* deficient mice using the *Ptf1a-Cre* system that resulted in complete *Arid1a* loss in acini, mosaic *Arid1a* deletion in duct cells and complete *Arid1a* retention in the islets. This suggests that in the ductal and endocrine compartments *Arid1a* was either required during development or its locus is inaccessible to Cre recombinase. We found that *Arid1a* loss alone was sufficient to generate PanIN and mucinous cysts that re-expressed progenitor markers such as PDX1 and HNF4A in a manner similar to that seen in pancreatitis and *Kras* activation.[@R21] Our work shows that *ARID1A* activity was necessary to maintain terminal differentiation of the pancreatic epithelium, and its loss resulted in a more dedifferentiated state that allowed neoplastic transformation, consistent with results recently reported by Kimura *et al.* and Livshits *et al*.[@R11] The concept that *ARID1A* is permissive for the process of tissue differentiation is also consistent with our previous work in the liver, where *Arid1a* loss resulted in downregulation of liver gene expression programmes involving coagulation, bile acid metabolism and xenobiotic metabolism.[@R16] In this way, *ARID1A* joins a group of other transcription factors and epigenetic modifiers, such *PTF1A*, *SOX9* and *BRG1*, as important players in maintaining pancreatic identity.[@R32]

We found that concurrent *Kras* activation and *Arid1a* loss led to IPMN formation, consistent with the findings of Kimura *et al*.[@R11] These lesions were predominantly of gastric subtype, but there were areas of pancreaticobiliary epithelium. Because we also observed ARID1A loss in human gastric and pancreaticobiliary IPMN resection samples, the cysts that formed from murine *Arid1a* deletion appeared to recapitulate human disease. Both our findings and those of Kimura *et al.* showed that only a small subset of mice with duct-specific *Kras* activation and *Arid1a* deletion developed dilated cyst with dysplasia. We extended this work by also incorporating the loss of one *Trp53* allele and found that a subset of mice developed PDAC. It is likely that additional tumour suppressor loss or activation of oncogenes such as *GNAS* and *RNF43*, the most commonly mutated genes in IPMN, play a more catalytic role in driving duct cells into IPMN.[@R43] In addition, other non-ductal cell autonomous effects may be required. For example, in the embryonic *Ptf1a-Cre* model, there was a significant inflammatory response induced by the activated *Kras* mutation in the acinar cells. Whether inflammation can accelerate IPMN formation is a topic that requires further study.

We also showed that *Arid1a* has tumour-suppressive effects in acinar cells. We observed that heterozygous *Arid1a* loss in conjunction with activated *Kras* in acini resulted in increased PanIN formation and reduced survival. Previous work by Hosada *et al.* that identified *ARID1A* mutations in high-grade PanIN hinted at *ARID1A*'s tumour-suppressive effects in the PanIN--PDAC axis.[@R44] We also found that *Arid1a* loss led to tumours that contained components of undifferentiated PDAC with rhabdoid and sarcomatoid features. These results are in line with several recent studies linking loss of *Smarcb1*, another SWI/SNF component, to a more mesenchymal or dedifferentiated PDAC phenotype.[@R45] Interestingly, the *Arid1a* null mice had a phenotype more similar to *Arid1a* wild-type mice in terms of PanIN formation and long-term survival. This likely speaks to the complicated context-dependent role of *Arid1a* in cancer biology consistent with what we had previously explored in the liver. There, we found that *Arid1a* was required in normal tissues to initiate cancer (ie, *Arid1a* was pro-tumorigenic) but in established cancers, *Arid1a* loss led to more aggressive cancer phenotypes (ie, *Arid1a* was tumour suppressive).[@R29]

While the PanIN to PDAC pathway is well established, the true cell of origin for human PDAC remains unclear. Using the transgenic mouse model, multiple groups have demonstrated that the acinar compartment can give rise to PanIN and PDAC in the setting of activating Kras mutations.[@R19] Gidekel Friedlander *et al.* showed that, in the setting of chronic injury, endocrine cells were also capable of giving rise to PanIN.[@R48] Our data showing that PanIN-associated PDAC arose from *Kras^G12D^; Trp53^f/+^; Sox9-CreER; Arid1a^f/f^* mice supports recent work by Lee *et al.*, who demonstrated that duct cells were capable of giving rise to PanIN and PDAC, using the *Sox9-CreER* line, and Bailey *et al.*, who generated PDAC using the *Hnf1b-CreERT* line.[@R49] Similarly, while *Sox9-CreER-*induced *Arid1a* loss led to cyst dilation, likely originating from the ductal compartment, this does not exclude the possibility that these lesions formed via a progenitor/ADM-like state, since a small percentage of acinar cells were labelled by *Sox9-CreER*.[@R32]

While *ARID1A* loss of function mutations have been identified in \~10% of PDAC samples in multiple large sequencing studies,[@R2] the mutational profiles of IPMN are currently being delineated with next-generation sequencing.[@R51] While some studies found *ARID1A* mutations in only a small number of resected IPMN,[@R54] Tan *et al*. showed that *ARID1A* was mutated in approximately 10% of all IPMN samples and was one of the more commonly mutated genes.[@R4] In addition, a recent study by Suenaga *et al.* found that about 15% of patients with IPMN containing high-risk features had *ARID1A* mutations detectable in pancreatic juice.[@R5] Other mechanisms for *ARID1A* downregulation are likely be involved as we found a significant proportion of resected IPMN with areas expressing little or no ARID1A. Similarly, Kimura *et al.* found that in their resected IPMN cohort, 22% of the samples lacked ARID1A on the protein level.[@R11]

Mechanistically, we found that genes involved in protein synthesis were overexpressed in *Arid1a*-deficient pancreata and that *ARID1A* knockdown in immortalised human pancreatic duct cells resulted in increased protein translation. In addition, we observed that *ARID1A* knockdown induced MYC expression, and concurrent knockdown of *ARID1A* and *MYC* in HPDE cells abrogated the increased translation, indicating that *ARID1A* loss operates, at least in part, through *MYC* activation. Intriguingly, both we and Kimura *et al.* observed that there was no increased proliferation in the *Arid1a*-null duct cells to explain the increase in duct size.[@R11] They had speculated that dilated cysts must thus occur due to mucin overproduction. Our finding that *Arid1a* loss led to increased protein translation supports that theory of IPMN formation. Based on the observation that mucinous cysts developed in mice with only *Arid1a* loss, perhaps *Arid1a* loss can be an initiating event that results in increased protein/mucin synthesis that mechanically increases duct size based on mass effect. A future acquisition of a driver mutation in genes such as *KRAS*, *GNAS* or *RNF43* then leads to transformation. This hypothesis would be consistent with the fact that many IPMN do not transform and progress to cancer.

The functional connection we identified between *Arid1a* loss and *Myc* expression is consistent with previous reports. First, Nagl *et al*. showed that the *Myc* promoter was a direct target of the SWI/SNF complex.[@R55] Second, Genovese *et al.* reported that the loss of *Smarcb1*, another component of the SWI/SNF complex, in PDAC cell lines activated *Myc* programmes that led to elevated protein synthesis and increased the aggressiveness of cancer cells.[@R45] Significantly, the increased protein synthesis rendered *Smarcb1* deficient cancer cell lines particularly sensitive to drugs that targeted the proteostatic stress response machinery, suggesting that this strategy may also be effective in *ARID1A* null IPMN and warrants further study. Furthermore, we found that the increase in protein production induced by *ARID1A* loss was not accompanied by activated mTOR signalling, which is an important activator of translation. This suggests that *ARID1A* loss may activate a translation programme specific to MYC activity. In addition, we also found that *ARID1A* loss led to increased H3K27ac marks at the loci of MYC targets and involved in protein translation, signifying increased transcriptional activity at these sites.

While increased protein synthesis has been considered a general hallmark of rapidly proliferating malignant cells, recent reports have demonstrated that elevated translation is necessary in only certain oncogenic contexts. Barna *et al.* showed that while elevated protein synthesis is required for *Myc*-driven lymphoma formation, moderating translation did not affect lymphomagenesis in the *Trp53-/-* background. These data suggest that protein synthesis is a specific requirement for *Myc* oncogenesis and not a function of carcinogenesis as a whole.[@R13] However, since *ARID1A* and SWI/SNF potentially influence loci across the entire genome, it is likely that *ARID1A* mediates pancreatic neoplasm formation and progression through a variety of other pathways in addition to ones involving protein synthesis. Further studies will be required to confirm that aberrant translation is a specific necessity for cyst formation resulting from *Arid1a* deletion and to elucidate additional pathways that are preferentially activated by SWI/SNF loss to drive cyst formation.

The survival rate for patients with PDAC remains dismal, and more than 90% of patients will die of the disease.[@R1] One strategy to improve outcomes is to intervene in patients with premalignant lesions, such as IPMN. Conversion from premalignancy to carcinoma significantly worsens survival as demonstrated by the fact that 50% of patients who undergo resection of localised disease still die within 2 years from recurrent disease.[@R56] However, there are no medical treatments for IPMN, and the only intervention available is prophylactic pancreatectomy, which carries morbidity and risk of death. Previous studies have described an antagonistic relationship between the SWI/SNF and PRC2 complexes, prompting preclinical and early phase clinical tests.[@R57] However, we found no difference in cyst size, or apoptosis or proliferation in cyst epithelium after treating a cohort of KCA mice with a potent EZH2 inhibitor. One possible explanation for this negative finding comes from the work of Kim *et al.*, who found that in *KRAS* gain-of-function mutants EZH2 structural inhibition, rather than functional inhibition of the catalytic site, was essential to induce apoptosis.[@R58]

In conclusion, we have identified *ARID1A* as a pancreatic tumour suppressor that acts by repressing *KRAS-*induced PanIN and IPMN formation. *ARID1A* loss leads to increased MYC expression, elevated protein synthesis and a globally activated chromatin state. Continued insights into the mechanisms that drive premalignant PDAC lesions may lead to novel therapeutic strategies against this lethal disease.
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